THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about $x_1, \dots, x_{N-1}, x_1, \dots, x_{N-1}, \dots, x_{N-1},$

If you have sold or transferred Shenzhen Hepalink Pharmaceutical Group Co., Ltd., And Andrewson Co., Ltd., Andrews

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

2022 WORK REPORT OF THE BOARD OF DIRECTORS 2022 WORK REPORT OF THE SUPERVISORY COMMITTEE 2022 ANNUAL REPORT AND ITS SUMMARY, H SHARES RESULTS ANNOUNCEMENT,

H SHARES 2022 ANNUAL REPORT, 2022 CORPORATE GOVERNANCE REPORT AND 2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

2022 FINAL FINANCIAL REPORT 2022 PROFIT DISTRIBUTION PROPOSAL RE-APPOINTMENT OF AUDITORS OF THE COMPANY

ELECTION OF THE SIXTH SESSION OF THE BOARD
REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF
THE SIXTH SESSION OF THE BOARD

ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND CASH FLOW MANAGEMENT
USING INTERNAL FUNDS

APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO CERTAIN BANKS FOR 2023
AMENDMENT OF ARTICLES OF ASSOCIATION

AND
NOTICE OF THE 2022 ANNUAL GENERAL MEETING

CONTENTS

				Page
DEFIN	ITIO	NS		1
LETTE	ER FR	OM THI	E BOARD	3
1	l.	, , 1 , <u>1</u>	ç	4
2	2.		\dots λ A λ λ λ λ λ λ λ	
		. 202	22	4
		. 202	22	5
			22 A	5
		. 202	22x _ 1x x 1 2	5
		. 202	22	5
		<i>1</i> .	_T 1 ₁	6
		n. 1		6
		<i>m</i> .		7
		· 1		7
		. 1	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	9
		, A.	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	9
		,,. A	A A	9
3	3.	A, , i]	$\mathcal{L}_{\mathcal{L}} = \mathcal{L}_{\mathcal{L}} = $	9
4	1	▼ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	- п	10
5	5.		. _r	11
APPEN	NDIX	I – P	ROFILES OF THE PROPOSED SIXTH SESSION OF THE BOARD	12
APPEN	NDIX	II – A	MENDMENT OF ARTICLES OF ASSOCIATION	18
NOTIC	CE OF	THE 20	22 ANNUAL GENERAL MEETING	20
		л. г.		. <i>V</i>

DEFINITIONS

In this circular, unless the context otherwise requires, the following terms shall have the following meanings:

7A.

DEFINITIONS

- 7. A. χ 14, 2023, χ 7. χ 7. χ 7. χ 7. χ 7. χ 8. χ 8. χ 8. χ 8. χ 8. χ 9. χ 10. χ 10.

- $7 \frac{1}{1} \cdot \frac{1}{1} \cdot$

- 7 1 1 1 1 1 1 1
- 7 Let $X^{(i)}$ $X^{(i)}$



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability) (Stock code: 9989)

Executive Directors:

(Chairman of the Board)
(Deputy General Manager)
(General Manager)

Independent non-executive Directors:

Registered office in the PRC:

Principal place of business in Hong Kong:

A 20, 2023

To the Shareholders

,

2022 WORK REPORT OF THE BOARD OF DIRECTORS 2022 WORK REPORT OF THE SUPERVISORY COMMITTEE 2022 ANNUAL REPORT AND ITS SUMMARY, H SHARES RESULTS ANNOUNCEMENT, H SHARES 2022 ANNUAL REPORT, 2022 CORPORATE GOVERNANCE REPORT AND 2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2022 FINAL FINANCIAL REPORT 2022 PROFIT DISTRIBUTION PROPOSAL RE-APPOINTMENT OF AUDITORS OF THE COMPANY ELECTION OF THE SIXTH SESSION OF THE BOARD REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF THE SIXTH SESSION OF THE BOARD ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND **CASH FLOW MANAGEMENT**

USING INTERNAL FUNDS
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO
CERTAIN BANKS FOR 2023
AMENDMENT OF ARTICLES OF ASSOCIATION

1. INTRODUCTION

- (4) 2022 = 1 = 1 = 1 = 1
- $(5) \qquad 2022 \qquad \qquad 1 \qquad 1 \qquad 1 \qquad 1 \qquad \dots \qquad 1$

- (9)

- $(12) \qquad , \qquad \qquad , \qquad A_{\lambda_1} \ldots A_{\lambda_{n-1}} \ldots$

2. MATTERS TO BE CONSIDERED AT THE ANNUAL GENERAL MEETING

i. 2022 Work Report of the Board of Directors

ii. 2022 Work Report of the Supervisory Committee

iii. 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report

 $\frac{1}{1} \cdot \frac{1}{1} \cdot \frac{1}$

iv. 2022 Final Financial Report

 $\frac{2022}{1} = \frac{1}{1} = \frac$

v. 2022 Profit Distribution Proposal

vi. Re-appointment of auditors of the Company

vii. Election of the sixth session of the Board

 $1.1 \cdot 1 \cdot 1 \cdot 1 \cdot 1 \cdot 3.4 \cdot A_{x} \cdot A_{x} \cdot 14 \cdot A_{x} \cdot 14 \cdot A_{x} \cdot A_{x}$ $m{x}_1, \dots, m{x}_{N-1}, \dots, m{x}_{N-1}, \dots, m{x}_{N-1}, m{x}_{N-1}, \dots, m{$ the state of the s $_{\Gamma}$ = $_{\gamma}$, $_$ $\mathbf{L}_{(Y)} \ldots = \mathbf{L}_{(Y)} \mathbf{L}_{(Y)} \ldots \mathbf{L}_{(Y)} , \quad \text{i.i.} \quad \mathbf{L}_{(Y)} \ldots \mathbf{L}$ $= \frac{1}{1} + \frac{1}{2} \frac{1}{1}$ $oxed{\mathcal{L}} = oxed{\mathcal{L}} oxed{\mathcal{L} oxed{\mathcal{L}} oxed{\mathcal{L} oxed{\mathcal{L}} oxed{\mathcal{L}} oxed{\mathcal{L}} oxed{\mathcal{L}} oxed{\mathcal{L}} oxe$ $\| \cdot \cdot \|_{L^{\infty}(L^{\infty})} = \| \cdot \|_{L^{\infty}(L^{\infty})} + \| \cdot \|_{L^{\infty}(L^{\infty}$ $_{\Gamma}$, $_{\Gamma}$ $oldsymbol{arphi}_{i}$, $oldsymbol{arphi}_$ -... $oldsymbol{\epsilon}_{-1}$, $oldsymbol{\epsilon}_{-1}$

 A_{i} , A_{i} , A

viii. Remuneration of independent non-executive Directors of the sixth session of the Board

ix. Election of the sixth session of the Supervisory Committee

 $\mathcal{L} = \frac{1}{N} \mathcal{L} = \frac{1}{N} \mathcal{L}$

に I (唐海均), I 44, I (本) (I (I) (I)

x. Purchase of Wealth Management Products and Cash Flow Management Using Internal Funds

xi. Application for Credit Line and Providing Guarantee to Certain Banks for 2023

(29, 2023) (30, 30

xii. Amendment of Articles of Association

2023. $A_{X_1} = A_{X_1} = A_{X_1}$

3. ANNUAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS OF H SHARES

 $= \frac{1}{1} \frac{$

29, 2023 31,

4. VOTING BY POLL

5. RECOMMENDATION

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Li Li

Chairman

APPENDIX I

PROFILES OF THE PROPOSED SIXTH SESSION OF THE BOARD

Non-independent Directors

(i) Mr. Li Li

(ii) Ms. Li Tan

 $x_1 = x_1 = x_2 = x_1 = x_2 = x_2 = x_2 = x_3 = x_4 = x_4$

A 1998. A 1 2007; A 1 2007; A 1 2010; A 1 2010; A 2010; A 2016.

PROFILES OF THE PROPOSED SIXTH SESSION OF THE BOARD

(iii) Mr. Shan Yu

(iv) Mr. Zhang Ping

Independent Non-Executive Directors

(v) Dr. Lu Chuan

 $oxed{\mathcal{L}}_{\mathbf{T}}$

PROFILES OF THE PROPOSED SIXTH SESSION OF THE BOARD

 A_{\cdot} , A_{\cdot}

(vi) Mr. Huang Peng

1949, 1949

 $\mathbf{A}_{\cdot\cdot\cdot\cdot}$, $\mathbf{A}_{\cdot\cdot\cdot}$, $\mathbf{A}_{\cdot\cdot\cdot}$, $\mathbf{A}_{\cdot\cdot\cdot}$, $\mathbf{A}_{\cdot\cdot\cdot}$, $\mathbf{A}_{\cdot\cdot\cdot}$

(vii) Mr. Yi Ming

| (易銘), 1 46, 1977, 19

 $A, \ldots, z = \ldots = \sum_{\lambda = 1}^{n} \ldots \sum_{\lambda = 1}^{n}$

PROFILES OF THE PROPOSED SIXTH SESSION OF THE BOARD

Existing Provisions of the Articles of Association	Proposed Amendments to the Articles of Association
$\begin{bmatrix} \lambda & \sigma & \cdots & \lambda & \sigma & \cdots & I_{n+1} & \cdots & \cdots & \cdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & \cdots & \cdots & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & 1 & \cdots & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & \vdots \\ (\lambda & 1 & \cdots & \vdots & \vdots & \vdots & $	$\begin{bmatrix} \cdot & A & \cdot & (\cdot - \frac{1}{X} \dots \frac{1}{$
. , , , , , , , , , , , , , , , , , , ,	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Article 97 A , , , , , , , , , , , , , , , , , ,	Article 97 A , , , , , , , , , , , , , , , , , ,
A \cdot	

Existing Provisions of the Articles of Association	Proposed Amendments to the Articles of Association
A \cdot	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Article 150	Article 150
Article 156	Article 156
Article 158	Article 158



ORDINARY RESOLUTION

8. $I_{Y} = I_{Y} = I$

SPECIAL RESOLUTION

9. $A_{\lambda_1} \dots A_{\lambda_{N-1}} \dots A$

ORDINARY RESOLUTIONS

- - 11.04 $X = \bigcup_{X \in X} \mathbf{1}_{X} = X = \bigcup_{X \in X} \mathbf{1}_{X} = \sum_{X \in X} \mathbf{1}$

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Li Li

Chairman

A 20, 2023

Notes:

- 3. $\sum_{Y \in \mathcal{X}} \mathbf{1} = \sum_{X \in \mathcal{X}} \sum_{Y \in \mathcal{X}} \mathbf{1} = \sum_{Y \in \mathcal{X}} \mathbf{1} = \sum_{X \in$
- 5. $\sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n}$
- 6. A $_{X}$ /2 $_{Z}$ $_{Z}$
- 7. $A_{||} \cdot x^{||} \cdot A_{||} \cdot A_{||}$
- - Q = (x, 1) + (x, 2) + (x, 3) + (x, 3)